Volume 55, Issue 6, Pages (June 1999)

Slides:

Advertisements

Similar presentations

Acute Renal Failure: Only three possible causes: 1. Inadequate perfusion 2. Intrinsic renal damage 3. Obstruction to the outflow of urine.

Advertisements

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Volume 61, Issue 2, Pages (August 2014)

Volume 62, Issue 6, Pages (December 2002)

Reduced renal function in patients with simple renal cysts

Treatment of acute renal failure

Volume 54, Issue 2, Pages (August 1998)

Long-term evolution of cardiomyopathy in dialysis patients

Diagnosis and Management of Chronic Kidney Disease

Sushrut S. Waikar, Venkata S. Sabbisetti, Joseph V. Bonventre

Blaithin A. McMahon, Patrick Thomas Murray Kidney International

A trial of thyroxine in acute renal failure

Volume 67, Issue 6, Pages (June 2005)

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets David M. Spiegel, Kate Brady Kidney.

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

Better nephrology for mice—and man

Volume 54, Issue 4, Pages (October 1998)

Volume 77, Issue 8, Pages (April 2010)

Volume 60, Issue 5, Pages (November 2001)

Volume 83, Issue 6, Pages (June 2013)

Volume 55, Issue 1, Pages (January 1999)

Comorbidity and confounding in end-stage renal disease

Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load

Insulin resistance in African Americans

Volume 61, Issue 6, Pages (June 2002)

Volume 62, Issue 6, Pages (December 2002)

Treatment of acute renal failure

Volume 84, Issue 3, Pages (September 2013)

Volume 56, Issue 3, Pages (September 1999)

Elke Wühl, Otto Mehls, Franz Schaefer Kidney International

Volume 61, Issue 4, Pages (April 2002)

Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients Denis Fouque, Susy C. Peng, Eshan Shamir, Joel.

Peritoneal dialysis adequacy and risk of death

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 73, Issue 5, Pages (March 2008)

Proteinuria and hypertensive nephrosclerosis in African Americans

Methods for guideline development

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 56, Issue 2, Pages (August 1999)

Reduced renal function in patients with simple renal cysts

Volume 63, Issue 2, Pages (February 2003)

Volume 78, Issue 5, Pages (September 2010)

Volume 62, Issue 6, Pages (December 2002)

Michael W. Steffes, Derek Schmidt, Rebecca Mccrery, John M. Basgen

Volume 57, Issue 1, Pages (January 2000)

Harold M. Aukema, Ihsan Housini Kidney International

Volume 80, Issue 3, Pages (August 2011)

Volume 74, Issue 5, Pages (September 2008)

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

It's not over till the last glomerulus forms

Volume 60, Issue 3, Pages (September 2001)

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

Volume 55, Issue 6, Pages (June 1999)

Volume 64, Issue 2, Pages (August 2003)

A trial of thyroxine in acute renal failure

Renal blood flow in experimental septic acute renal failure

Volume 64, Issue 4, Pages (October 2003)

T cells and T-cell receptors in acute renal failure

Volume 61, Issue 1, Pages (January 2002)

Volume 67, Issue 5, Pages (May 2005)

Volume 53, Issue 5, Pages (May 1998)

Volume 57, Issue 2, Pages (October 2000)

Volume 67, Issue 4, Pages (April 2005)

Stephen Pastan, J. Michael Soucie, William M. McClellan

Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases Martina Franz, Wolfgang Woloszczuk,

A. Lauschke, U.K.M. Teichgräber, U. Frei, K.-U. Eckardt

Acute phosphate nephropathy

Volume 56, Issue 6, Pages (December 1999)

Presentation transcript:

Volume 55, Issue 6, Pages 2423-2432 (June 1999) Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure Raimund Hirschberg, Joel Kopple, Pamela Lipsett, Ernest Benjamin, Joseph Minei, Timothy Albertson, Mark Munger, Michael Metzler, Gary Zaloga, Michael Murray, Stephen Lowry, John Conger, Wade Mckeown, Michael O'Shea, Robert Baughman, Kenneth Wood, Marilyn Haupt, Roger Kaiser, Hank Simms, David Warnock, Warren Summer, Raymond Hintz, Brian Myers, Kathrine Haenftling, William Capra, Marilyn Pike, Hans-Peter Guler Kidney International Volume 55, Issue 6, Pages 2423-2432 (June 1999) DOI: 10.1046/j.1523-1755.1999.00463.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 (A) Daily urine excretion in study participants randomly assigned to recombinant human insulin-like growth factor I (rhIGF-I; ▪; N = 35) or placebo (□; N = 37). Data are mean ± sd. Values are not significantly different. (B) Daily urine excretion in subjects who were oliguric or anuric at baseline (urine volume of less than 500ml/24hr) and treated with rhIGF-I (▪; N = 12) or placebo (□; N = 11), respectively. Data are mean ± sd. Values are not significantly different. Kidney International 1999 55, 2423-2432DOI: (10.1046/j.1523-1755.1999.00463.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 (A) Glomerular filtration rate measured as clearance of iothalamate in all study participants with sufficient urine flow rates, receiving rhIGF-I (▪; N = 22) or placebo (□; N = 27). Data are mean ± sd. Values are not significantly different. (B) Glomerular filtration rate in subjects who were oliguric at baseline and who had urine flow rates sufficient for the measurement of iothalamate clearance treated with rhIGF-I (▪; N = 7) or placebo (□; N = 8), respectively. Data are mean ± sd. Values are not significantly different. Kidney International 1999 55, 2423-2432DOI: (10.1046/j.1523-1755.1999.00463.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 (A) Creatinine clearances in all subjects with sufficient urine flow rates, receiving rhIGF-I (▪) or placebo (□), respectively. Data are mean ± sd. Values are not significantly different. (B) Creatinine clearances in subjects who were oliguric at baseline receiving rhIGF-I (▪) or placebo (□). Data are mean ± sd. Values are not significantly different. Kidney International 1999 55, 2423-2432DOI: (10.1046/j.1523-1755.1999.00463.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Serum levels of IGF-binding protein-2 (A) and IGF-binding protein-3 (B) in subjects receiving rhIGF-I (▪) or placebo (). Data are mean ± sem. Kidney International 1999 55, 2423-2432DOI: (10.1046/j.1523-1755.1999.00463.x) Copyright © 1999 International Society of Nephrology Terms and Conditions